My Profile
Edit Profile
My Follows
My Wires
My Drafts
Analytics
Email Preferences
Sign Out
home
most popular
Latest
Buy Hold Sell
Alternatives in Focus
Series
Alternatives in Focus
Buy Hold Sell
Expert Insights
Fund in Focus
Growth
Income Series
Listed Series
Livewire Live
Meet The Adviser
Meet The Investor
Outlook Series
Rapid Fire
Reporting Season
Success and More Interesting Stuff
The Pitch
The Rules of Investing
Undiscovered Funds
Views from the Top
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Weekend Report
Contributors
Find Funds
Newsletter
About Livewire
Advertising
Careers
Contact Us
Write a Wire
Notifications
Loading...
Write a wire
Account
My profile
My follows
My wires
My drafts
Analytics
Email preferences
Company
About Livewire
Advertising
Contact us
Sign out
Sign In
Join Free
Latest
Buy Hold Sell
Alternatives in Focus
Series
Alternatives in Focus
Buy Hold Sell
Fund in Focus
Growth
Income Series
Livewire Live
Meet The Investor
Rapid Fire
Reporting Season
Success and More Interesting Stuff
The Pitch
The Rules of Investing
Views from the Top
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Weekend Report
Find funds
Newsletter
biotech
Latest news and analysis on biotech
April 29, 2014 09:01
David Merkel from the Aleph Blog says It is wise to avoid the area of the market where issuance is well above average
Livewire News
Livewire
April 29, 2014 09:01
April 15, 2014 00:50
The US transport sector and the biotech sector are two extremes of the US market
John Robertson
PortfolioDirect
April 15, 2014 00:50
April 11, 2014 05:09
There's some interesting action going on in US equities today
Jay Soloff
Argonath Financial
April 11, 2014 05:09
Advertisement
April 10, 2014 15:21
At least one patient with diabetic limb ulcers will be pleased that they participated in Osprey Medical's (ASX:OSP) Limb Recovery trial
Matthijs Smith
Canaccord Genuity Australia
April 10, 2014 15:21
April 07, 2014 11:30
After Prana (ASX:PBT) announced a result we would rather forget from their Alzheimer's drug, the biotech sector closed down 7.9% last week
Matthijs Smith
Canaccord Genuity Australia
April 07, 2014 11:30
March 25, 2014 12:31
dorsaVi (ASX:DVL) is walking around with an impressive update on the commercialisation of its movement products
Matthijs Smith
Canaccord Genuity Australia
March 25, 2014 12:31
March 11, 2014 13:31
Last week, the small end of town was where all the action was in biotech-land with Biotron (ASX:BIT) up 97%, newcomer Innate Therapeutics (ASX:IIL) up 33% and...
Matthijs Smith
Canaccord Genuity Australia
March 11, 2014 13:31
February 05, 2014 17:38
Morgans Research maintain an add recommendation on GI Dynamics (GID) with a price target of $1.61
Livewire Equities
Livewire
February 05, 2014 17:38
January 28, 2014 09:55
Innate Immunotherapeutics (IIL) listed late in 2013 with Australian Ethical taking a cornerstone position in the float
Livewire Equities
Livewire
January 28, 2014 09:55
81-89 of 89
1
2
3
4
5
most
popular
Equities
Yes we're in a stock market bubble, no you shouldn't sell: T. Rowe Price's Scott Berg
Tom Stelzer,
Livewire Markets
Equities
The Magnificent Seven can’t carry the market forever
John Goetz,
Pzena Investment Management
Equities
2 global stocks Canopy believes are positioned for long-run compounding
Stephanie Gardner,
Livewire Markets
Equities
8 ASX names Macquarie says are ready to run in a rebound (plus a “least preferred” stock)
Vishal Teckchandani,
Livewire Markets
view all
Advertisement
